GLS and cancer: Here, we observed that cisplatin‐resistant cancer cells are more sensitive to ASNase, and unlike the targeted ferroptosis inducers and glutaminase inhibitor, ASNase sensitivity was consistent between the cisplatin‐resistant models, although elevated in the glutamine‐dependent HCC4006 model.